Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02587650 · ClinicalTrials.gov registry record · Phase 2
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02587650 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 1 participants.
The verdict
NCT02587650, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Capmatinib
- OTHER Laboratory Biomarker Analysis
- DRUG Regorafenib
- DRUG Entrectinib
- DRUG Ceritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-03-26 |
| Est. Completion | 2018-07-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02587650
The ClinicalTrials.gov registry entry for NCT02587650 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capmatinib is the first listed.
NCT02587650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02587650 about?
NCT02587650 is a clinical study titled "Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma". This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell grow...
What is the current status of trial NCT02587650?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-03-26. Estimated completion is 2018-07-12.
What interventions are being tested in trial NCT02587650?
The interventions under investigation include: Capmatinib (DRUG), Laboratory Biomarker Analysis (OTHER), Regorafenib (DRUG), Entrectinib (DRUG), Ceritinib (DRUG).
Who is sponsoring clinical trial NCT02587650?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.